Thyroid Associated Ophthalmopathy Clinical Trial
Official title:
The Therapeutic Effect of Combination of Orbital Compression Surgery and Strabismus Surgery in Patients With Moderate to Severe Thyroid Associated Ophthalmopathy
The purpose of this study is to determine whether combination of orbital compression surgery with strabismus surgery is better than strabismus surgery after orbital compression surgery in the treatment of moderate-to-severe thyroid associated ophthalmopathy
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - moderate-to-severe thyroid associate ophthalmopathy - CAS=3 score - monocular strabismus,deviation=20° or 35? - stable thyroid function for at least 6 months, confirmed by an endocrinologist Exclusion Criteria: - any previous disease in the study eye. - any previous systematic disease |
Country | Name | City | State |
---|---|---|---|
China | Zhongshan Ophthalmic Center, Sun Yat-sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | quality of life ,measured by GO-QoL(quality of life with Grave's Orbitopathy) . | All GO-QoL questions were scored as 'severely limited' (one point), 'a little limited' (two points) or 'not limited at all' (three points). The questions 1-8 for visual functioning (VF) and questions 9-16 for appearance (AP)were summed to produce two raw scores from 8 to 24 points and then transformed to two total scores from 0 to 100 by the following formula: total score = [(raw score - 8)/16 9 100]. In both cases, higher total scores indicate better QoL. When there were missing values, total scores were calculated for the remaining completed items. The transformation was then adjusted to total score = [(raw score - *)/(2x*) x100] where * is the number of completed items. | 6 weeks after surgery | |
Primary | quality of life, measured by GO-QoL(quality of life with Grave's Orbitopathy) . | All GO-QoL questions were scored as 'severely limited' (one point), 'a little limited' (two points) or 'not limited at all' (three points). The questions 1-8 for visual functioning (VF) and questions 9-16 for appearance (AP)were summed to produce two raw scores from 8 to 24 points and then transformed to two total scores from 0 to 100 by the following formula: total score = [(raw score - 8)/16 9 100]. In both cases, higher total scores indicate better QoL. When there were missing values, total scores were calculated for the remaining completed items. The transformation was then adjusted to total score = [(raw score - *)/(2x*) x100] where * is the number of completed items. | 6 months | |
Secondary | strabismus status | angle of deviation including up-gaze, down-gaze ,left and right-gaze | 6 weeks after surgery | |
Secondary | strabismus status | angle of deviation including up-gaze, down-gaze ,left and right-gaze | 6 months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06087731 -
Efficacy and Safety of Tocilizumab for TAO
|
Phase 2 | |
Recruiting |
NCT05110040 -
Multi-model Image of Immunosuppressive Agents in TAO
|
N/A | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03107078 -
Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial
|
Phase 4 | |
Recruiting |
NCT04548284 -
Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO
|
Phase 3 | |
Recruiting |
NCT03515863 -
Natural History and Risk Factors of TAO
|
||
Not yet recruiting |
NCT06392906 -
Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)
|
Phase 3 | |
Recruiting |
NCT06226545 -
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
|
Phase 2 | |
Completed |
NCT00150111 -
Rituximab in the Treatment of Graves' Disease
|
Phase 1/Phase 2 | |
Completed |
NCT03110848 -
Effects of Atorvastatin in Graves' Orbitopathy (GO)
|
Phase 2 | |
Recruiting |
NCT04662190 -
Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.
|
N/A | |
Active, not recruiting |
NCT05276063 -
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03131726 -
Treatment of Graves´Ophthalmopathy With Simvastatin (GO-S)
|
Phase 3 | |
Completed |
NCT02766660 -
Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy
|
N/A | |
Active, not recruiting |
NCT06269393 -
A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy
|
Phase 3 | |
Not yet recruiting |
NCT03098225 -
A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy
|
Phase 4 | |
Recruiting |
NCT05112211 -
Multi-model Image of Doxycycline in TAO
|
N/A |